agilon health Third Quarter 2026 Earnings Conference - AGILON HEALTH INC

Financial Performance:

• Q3 2026 revenue reached $1.5 billion, a 6% year-over-year increase driven by constructive CMS benchmarks, favorable contracting, and higher revenue from Burden of Illness programs (risk adjustment true-ups).
• Medical expense trends improved, with the first half of 2026 estimated in the low 6% range and Q3 trend in the low 7% range due to prudent reserving and favorable prior-year development.
• Medical Services Expense Ratio (MSER) for Q3 was 88.5%, down significantly from 104% in Q3 2025, reflecting higher medical services revenue and lower costs.
• Adjusted EBITDA for Q3 was $64 million (up from a $91 million loss in Q3 2025), exceeding guidance by approximately $64 million due to favorable prior-year development, risk adjustment improvements, and strong ACO performance.
• Full Year 2026 guidance was raised: Revenue to $5.88 billion, MSER to 90.4%, and Adjusted EBITDA to approximately $150 million.
• Balance sheet strength: Ended Q3 with $312 million in cash and marketable securities plus $74 million in off-balance sheet ACO cash; year-end 2026 cash outlook raised to at least $175 million.
• ACO segment delivered $11 million in adjusted EBITDA for Q3 (vs. breakeven guidance), with 2025 performance contributing an additional $18 million year-to-date.

Guidance and Future Outlook:

• 2027 Medicare Advantage (MA) membership expected to see a modest, favorable contracting benefit, though less pronounced than the 80% repricing in 2026.
• ACO membership projected to grow 40-50% in 2027, increasing from ~112,000 to ~160,000 members, primarily through the Medicare Shared Savings Program (MSSP) while balancing with full-risk MA models.
• 2028 and beyond strategy involves measured external growth in new markets with a 12-18 month onboarding timeline; new partners are expected to sign contracts in 2027 for 2028 impact.
• Quality metrics for 2025 show a 3% increase in gap closure and a 4.2-star performance; expected to have 75% of members in 4+ star plans for payment year 2028 (up from 71% nationally).
• Full 2027 guidance regarding total ACO membership and adjusted EBITDA contribution to be provided in February.

Business Segments and Product Lines:

• Burden of Illness: Primary driver of revenue growth, utilizing risk adjustment and early diagnosis to identify high-risk patients and drive revenue through better coding and treatment.
• Clinical Pathways: Heart Failure (CHF) is a key proof point; virtual pharmacy rollout is ongoing to improve adherence to Guideline-Directed Medical Therapy (GDMT). New pathways for Dementia and Lung Health are expanding to one-third of markets.
• ACO Business: Recently added three relationship expansions totaling nearly 50,000 MSSP members who already hold full-risk MA contracts, demonstrating deepening trust and model scalability.
• Technology: Investments in AI and data capabilities to reduce administrative burden, provide point-of-care insights, and identify care gaps earlier.
• Membership: MA membership stood at 454,000 (down ~10% YoY) due to disciplined market exits and contracting strategy; includes ~39,000 members in care coordination fees.

Market and Competitive Landscape:

• Agilon positions itself at the center of value-based care evolution, leveraging local physician proximity and data-driven insights.
• Strong inbound demand from physician groups; pipeline for new partnerships remains robust.
• Competing on operational excellence and quality outcomes rather than just scale, with a focus on reducing performance variability across the network.
• Successfully extended value-based care models from Medicare Advantage beneficiaries to traditional Medicare (MSSP) populations within existing partner organizations.

Risks and Challenges:

• Cost Trends: While favorable in H1 2026, management maintains a prudent outlook with 7% cost trends embedded in the Q4 guide.
• Contracting: Approximately 50% of the book is in the 2027 contracting cycle; risk exists in securing favorable economics if payers do not fully recognize value delivered.
• Data Coverage: Medical data pipeline coverage is at ~85%; reaching low-to-mid 90% requires slower, resource-intensive implementations with remaining smaller payers.
• Implementation Lag: New market onboarding requires 12-18 months to establish infrastructure and workflows before financial impact is realized.

Management Commentary and Tone:

• Tone is highly confident and disciplined, emphasizing "operational execution" and "measured growth" over aggressive expansion.
• Management highlighted a specific patient success story (72-year-old with undiagnosed heart failure) to illustrate the tangible value of their clinical pathways.
• Emphasis on "embedded growth" within existing partner networks rather than rapid, untested market entry.
• Reiterated commitment to reducing variability and ensuring best practices are consistently deployed across the entire network.

Analyst Questions and Answers:

• Growth Timing (Truist): Confirmed new market contracts signed in 2027 will impact 2028 due to implementation timelines; no shift to 2029.
• Cost Trends (Truist): Confirmed H1 2026 trends restated to low 6%; Q3 trend remains in low 7% range with limited paid claims visibility.
• Risk Model (TD Cowen): New external partnerships will move directly into risk-bearing arrangements rather than starting with care coordination fees.
• STARs Incentives (Barclays): Confirmed Agilon will participate in upside bonus revenue as payer STARs recover, given their strong performance on relevant metrics.
• Q4 Seasonality (Barclays): Q4 is historically the lowest earning quarter; guidance assumes normal seasonality and 7% cost trend, with reduced Part D risk exposure (down to ~15% from 30%).
• ACO Penetration (Jefferies): ACO business represents a significant opportunity for deeper penetration within existing partners, currently utilized by half of the partner base.
• Data Infrastructure (William Blair): Data pipeline coverage is in the mid-80% range; target is low-to-mid 90% long-term, though progress on the remaining portion will be slower.

Other Key Points:

• Virtual investor event "Driving Performance at Scale" scheduled for November 17th to detail Agilon's technology-enabled clinical framework.
• 2025 performance metrics: 75% of members in 4+ star plans (projected), with 5-star performance in cardiovascular, hypertension, and cancer screening measures.
• ACO savings: 2024 performance year generated $229 million in gross savings with an average quality score of 96%.
• 2027 focus areas include strengthening operational execution, disciplined payer contracting (addressing 50% of the book), and enhancing data capabilities for actionable insights.